Dentsply Sirona (XRAY)
(Real Time Quote from BATS)
$23.34 USD
-0.15 (-0.64%)
Updated Nov 4, 2024 03:55 PM ET
After-Market: $23.33 -0.01 (-0.04%) 4:16 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.34 USD
-0.15 (-0.64%)
Updated Nov 4, 2024 03:55 PM ET
After-Market: $23.33 -0.01 (-0.04%) 4:16 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
Zacks News
Merit Medical (MMSI) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 42% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong segmental performance.
Dentsply International (XRAY) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMN Healthcare (AMN) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect solid demand in some of the areas of its business.
OPKO Health (OPK) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.
What's in Store for West Pharmaceutical's (WST) Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business.
Baxter (BAX) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results are likely to reflect growth in its Acute Therapies business.
Why the Earnings Surprise Streak Could Continue for Dentsply (XRAY)
by Zacks Equity Research
Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
3 Medical Products Stocks Poised to Beat This Earnings Season
by Trina Mukherjee
The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.
DaVita's (DVA) Collaboration to Aid in Kidney Care Needs
by Zacks Equity Research
DaVita's (DVA) work with transplant providers and kidney doctors is likely to slow CKD progression and bolster access to home dialysis and kidney transplantation.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
DENTSPLY SIRONA's (XRAY) New Alliance to Boost Digital Dentistry
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) and 3Shape extend their partnership to simplify digitally oriented workflows for dentists and dental technicians.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woe persists.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter results benefit from strong segmental performance.
Dentsply International (XRAY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 4.62% and 4.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Nov 4 Earnings Roster: BDX, ZBH & More
by Trina Mukherjee
The Medical Product companies' Q3 results are likely to reflect huge adoption of their COVID-related support products. Let's see how BDX, ZBH, ABC and XRAY are poised ahead of their earnings releases.
Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) third-quarter results are likely to reflect strong segmental performance.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woe persists.
XRAY vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
Inogen (INGN) Stock Loses 26.7% In Spite of Q2 Earnings Beat
by Zacks Equity Research
Inogen's (INGN) second-quarter results benefit from higher revenues across its segments.
LHC Group (LHCG) Stock Loses 11.9% Despite Q2 Earnings Beat
by Zacks Equity Research
LHC Group's (LHCG) second-quarter results benefit from organic growth in both home health and hospice admissions.
DENTSPLY SIRONA (XRAY) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter results benefit from strong segmental performance.
Dentsply International (XRAY) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 9.23% and 6.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?